Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alkalifah A, Alsantali A, Wang E, McElwee K, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology and pathogenesis. J Am Acad Dermatol. 2010;62:177–88.
Alkhalifa A. Topical and intralesional therapies for alopecia areata. Dermatol Ther. 2011;24:355–63.
Arca E, Musabak U, Akar A, Erbil AH, Tastan HB. Interferon gamma in alopecia areata. Eur J Dermatol. 2004;14(1):33–6.
Bodemer C, Peuchmar M, Fraitag S, Chatenaud L, Brousse N, De Prost Y. Role of cytotoxic T cells in chronic alopecia areata. J Invest Dermatol. 2000;114:112–6.
Carroll JM, McElwee K, King L, Byrne MC, Sundberg J. Gene array profiling and immunomodulation studies define a cell mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol. 2002;119:392–402.
Dy L, Whiting D. Histopathology of alopecia areata, acute and chronic: why is it important to the clinician? Dermatol Ther. 2011;24:369–74.
Freyschmidt-Paul P, McElwee K, Hoffman R, et al. Interferon gamma deficient mice are resistant to the development of AA. Br J Dermatol. 2006;155:515–21.
Freyschmidt-Paul P, Hoffman R, McElwee K. Alopecia areata. In: Blume-Peytavi U, Tosti A, Whiting D, Trueb R, editors. Hair growth and disorders. Germany: Springer; 2008.
Freyschmidt-Paul P, McElwee K, Hoffman R. Alopecia areata. In: Hertl M, editor. Autoimmune diseases of the skin: pathogenesis, diagnosis, management. New York: Springer; 2012.
Gilhar A. Collapse of immune privilege in alopecia areata: coincidental or substantial? J Invest Dermatol. 2010;130:2535–7.
Gilhar A, Pillar T, Assy B, David M. Failure of passive transfer of serum from patients with alopecia areata and alopecia universalis to inhibit hair growth in transplants of human scalp skin grafted onto nude mice. Br J Dermatol. 1992;126:166–71.
Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl Med J. 2012;16:1515–25.
Ito T, Ito N, Saathoff M, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008;128:1196–206.
Jagielska D, Redler L, Brockschmidt F, et al. Follow up of the first genome wide association scan in alopecia areata: IL 13 and KIAA0350 as susceptibility loci supported with genome wide significance. J Invest Dermatol. 26 April 2012. doi: 10.1038/jid.1012.129 (advance online publication).
Kang H, Wu WY, Lo BK, et al. Hair follicles form alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J invest Dermatol Nov. 2012;130(11):2677–80.
Kurtev A, Iliev E. Thyroid autoimmunity in children and adolescents with alopecia areata. Int J Dermatol. 2005;44:457–61.
McElwee K, Hoffman R. Alopecia areata – animal models. Clin Exp Dermatol. 2002;27:414–21.
McElwee K, Hoffman R, Freyschmidt-Paul P, et al. Resistance to alopecia areata in C3H/HeJ mice is associated with increased expression of regulatory cytokines and a failure to recruit CD4+ and CD8+ cells. J Invest Dermatol. 2002;119:1426–33.
McElwee K, Freyschmidt-Paul P, Hoffman R, et al. Transfer of CD8+ cells induce localized hair loss while CD4+/CD25-cells promote systemic alopecia areata and CD4+/CD25+ cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol. 2005;124:947–57.
Petukhova L, Duvic M, Hordinsky M, et al. Genome wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466:113–7.
Safavi K. Prevalence of alopecia areata in the first national health and nutrition examination survey. Arch Dermatol. 1992;128:702.
Shapiro J. Alopecia Areata. In: Shapiro J, editor. Hair loss: principles of diagnosis and management of alopecia. London: Martin Duniz; 2002.
Strober B, Menon K, McMichael A, et al. Alefacept for severe alopecia areata. Arch Dermatol. 2009;145:1262–6.
Tobin DJ. Characterization of hair follicles antigens targeted by the anti-hair follicle immune response. J Invest Dermatol Symp proc. 2003;8:176–81.
Tosti A, Piraccine B, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05 % under occlusion in the treatment of alopecia totalis/universalis. J Am Acad. 2003;49:96–8.
Tosti A, Iorizzo M, Botta G, Milani M. Efficacy and safety of clobetasol propionate 0.05% foam in alopecia areata: a randomized, double blind, placebo controlled trial. J Eur Acad Dermatol Venereol. 2006;20:1243–7.
Wang E, McElwee K. Etiopathogenesis of alopecia areata: why do our patients get it? Dermatol Ther. 2011;24:337–47.
Wang SJ, Shohat T, Vadheim C, Shellow W, Edwards J, Rotter J. Increased risk for type I (insulin-dependent) diabetes in relatives of patients with alopecia areata. Am J Med Genet. 1994;51:234–9.
Whiting D. Histopathologic features of alopecia areata. Arch Dermatol. 2003;139:1555–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this entry
Cite this entry
Bunagan, M.J.K., Banka, N., Shapiro, J. (2014). Alopecia Areata. In: Mackay, I.R., Rose, N.R., Diamond, B., Davidson, A. (eds) Encyclopedia of Medical Immunology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-84828-0_272
Download citation
DOI: https://doi.org/10.1007/978-0-387-84828-0_272
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-84827-3
Online ISBN: 978-0-387-84828-0
eBook Packages: MedicineReference Module Medicine